BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dugovic C, Shelton JE, Yun S, Bonaventure P, Shireman BT, Lovenberg TW. Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism. Front Neurosci 2014;8:28. [PMID: 24592208 DOI: 10.3389/fnins.2014.00028] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Jacobson LH, Chen S, Mir S, Hoyer D. Orexin OX2 Receptor Antagonists as Sleep Aids. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 105-36. [DOI: 10.1007/7854_2016_47] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
2 Hoyer D, Jacobson LH. Orexin Receptor Antagonists. Curr Sleep Medicine Rep 2017;3:342-53. [DOI: 10.1007/s40675-017-0099-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opinion on Drug Metabolism & Toxicology 2020;16:1063-78. [DOI: 10.1080/17425255.2020.1817380] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
4 Nevárez N, de Lecea L. Hypocretin and the Regulation of Sleep-Wake Transitions. Handbook of Sleep Research. Elsevier; 2019. pp. 89-99. [DOI: 10.1016/b978-0-12-813743-7.00006-2] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 van der Ark PD, Golor G, van Nueten L, Nandy P, de Boer P. Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects. J Psychopharmacol 2018;32:1330-40. [DOI: 10.1177/0269881118791521] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
6 Christopher JA, Aves SJ, Brown J, Errey JC, Klair SS, Langmead CJ, Mace OJ, Mould R, Patel JC, Tehan BG, Zhukov A, Marshall FH, Congreve M. Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties. Med Chem Commun 2015;6:947-55. [DOI: 10.1039/c5md00027k] [Cited by in Crossref: 11] [Article Influence: 1.6] [Reference Citation Analysis]
7 Han Y, Yuan K, Zheng Y, Lu L. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. Neurosci Bull 2020;36:432-48. [PMID: 31782044 DOI: 10.1007/s12264-019-00447-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
8 Berdyyeva T, Otte S, Aluisio L, Ziv Y, Burns LD, Dugovic C, Yun S, Ghosh KK, Schnitzer MJ, Lovenberg T, Bonaventure P. Zolpidem reduces hippocampal neuronal activity in freely behaving mice: a large scale calcium imaging study with miniaturized fluorescence microscope. PLoS One 2014;9:e112068. [PMID: 25372144 DOI: 10.1371/journal.pone.0112068] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
9 Christopher JA. Small-molecule antagonists of the orexin receptors. Pharm Pat Anal 2014;3:625-38. [PMID: 25489915 DOI: 10.4155/ppa.14.46] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
10 Sanchez-Alavez M, Benedict J, Wills DN, Ehlers CL. Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal. Sleep 2019;42:zsz020. [PMID: 30715515 DOI: 10.1093/sleep/zsz020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
11 Bonaventure P, Dugovic C, Shireman B, Preville C, Yun S, Lord B, Nepomuceno D, Wennerholm M, Lovenberg T, Carruthers N, Fitz SD, Shekhar A, Johnson PL. Evaluation of JNJ-54717793 a Novel Brain Penetrant Selective Orexin 1 Receptor Antagonist in Two Rat Models of Panic Attack Provocation. Front Pharmacol 2017;8:357. [PMID: 28649201 DOI: 10.3389/fphar.2017.00357] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
12 Dale NC, Hoyer D, Jacobson LH, Pfleger KDG, Johnstone EKM. Orexin Signaling: A Complex, Multifaceted Process. Front Cell Neurosci 2022;16:812359. [DOI: 10.3389/fncel.2022.812359] [Reference Citation Analysis]
13 Recourt K, de Boer P, Zuiker R, Luthringer R, Kent J, van der Ark P, Van Hove I, van Gerven J, Jacobs G, van Nueten L, Drevets W. The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. Transl Psychiatry 2019;9:216. [PMID: 31481683 DOI: 10.1038/s41398-019-0553-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
14 Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med 2022. [PMID: 35043499 DOI: 10.1111/joim.13406] [Reference Citation Analysis]
15 Couvineau A, Voisin T, Nicole P, Gratio V, Abad C, Tan YV. Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases. Front Endocrinol (Lausanne) 2019;10:709. [PMID: 31695678 DOI: 10.3389/fendo.2019.00709] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
16 Gotter AL, Garson SL, Stevens J, Munden RL, Fox SV, Tannenbaum PL, Yao L, Kuduk SD, McDonald T, Uslaner JM, Tye SJ, Coleman PJ, Winrow CJ, Renger JJ. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators. BMC Neurosci 2014;15:109. [PMID: 25242351 DOI: 10.1186/1471-2202-15-109] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
17 Hoyer D, Allen A, Jacobson LH. Hypnotics with novel modes of action. Br J Clin Pharmacol 2020;86:244-9. [PMID: 31756268 DOI: 10.1111/bcp.14180] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
18 Aluisio L, Fraser I, Berdyyeva T, Tryputsen V, Shireman BT, Shoblock J, Lovenberg T, Dugovic C, Bonaventure P. Pharmacological or genetic orexin1 receptor inhibition attenuates MK-801 induced glutamate release in mouse cortex. Front Neurosci 2014;8:107. [PMID: 24904253 DOI: 10.3389/fnins.2014.00107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
19 Zhang Y, Ren R, Yang L, Zhou J, Sanford LD, Tang X. The effect of treating obstructive sleep apnea with continuous positive airway pressure on posttraumatic stress disorder: A systematic review and meta-analysis with hypothetical model. Neuroscience & Biobehavioral Reviews 2019;102:172-83. [DOI: 10.1016/j.neubiorev.2019.03.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
20 Letavic MA, Bonaventure P, Carruthers NI, Dugovic C, Koudriakova T, Lord B, Lovenberg TW, Ly KS, Mani NS, Nepomuceno D, Pippel DJ, Rizzolio M, Shelton JE, Shah CR, Shireman BT, Young LK, Yun S. Novel Octahydropyrrolo[3,4- c ]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate. J Med Chem 2015;58:5620-36. [DOI: 10.1021/acs.jmedchem.5b00742] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
21 Janto K, Prichard JR, Pusalavidyasagar S. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics. J Clin Sleep Med 2018;14:1399-408. [PMID: 30092886 DOI: 10.5664/jcsm.7282] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
22 Beuckmann CT, Ueno T, Nakagawa M, Suzuki M, Akasofu S. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation. Sleep 2019;42:zsz076. [PMID: 30923834 DOI: 10.1093/sleep/zsz076] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
23 Soya S, Sakurai T. Orexin as a modulator of fear-related behavior: Hypothalamic control of noradrenaline circuit. Brain Res 2020;1731:146037. [PMID: 30481504 DOI: 10.1016/j.brainres.2018.11.032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
24 Boss C, Roch C. Recent trends in orexin research—2010 to 2015. Bioorganic & Medicinal Chemistry Letters 2015;25:2875-87. [DOI: 10.1016/j.bmcl.2015.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
25 Brodnik ZD, Alonso IP, Xu W, Zhang Y, Kortagere S, España RA. Hypocretin receptor 1 involvement in cocaine-associated behavior: Therapeutic potential and novel mechanistic insights. Brain Res 2020;1731:145894. [PMID: 30071195 DOI: 10.1016/j.brainres.2018.07.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
26 Dell’osso B, Dobrea C, Cremaschi L, Arici C, Altamura AC. Wake-Promoting Pharmacotherapy for Psychiatric Disorders. Curr Psychiatry Rep 2014;16. [DOI: 10.1007/s11920-014-0524-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
27 Brodnik ZD, Bernstein DL, Prince CD, España RA. Hypocretin receptor 1 blockade preferentially reduces high effort responding for cocaine without promoting sleep. Behav Brain Res 2015;291:377-84. [PMID: 26049058 DOI: 10.1016/j.bbr.2015.05.051] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
28 Zhang Y, Ren R, Sanford LD, Yang L, Zhou J, Zhang J, Wing YK, Shi J, Lu L, Tang X. Sleep in posttraumatic stress disorder: A systematic review and meta-analysis of polysomnographic findings. Sleep Med Rev 2019;48:101210. [PMID: 31518950 DOI: 10.1016/j.smrv.2019.08.004] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
29 Greenwald MK, Moses TEH, Roehrs TA. At the intersection of sleep deficiency and opioid use: mechanisms and therapeutic opportunities. Transl Res 2021;234:58-73. [PMID: 33711513 DOI: 10.1016/j.trsl.2021.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Li SB, Nevárez N, Giardino WJ, de Lecea L. Optical probing of orexin/hypocretin receptor antagonists. Sleep 2018;41. [PMID: 30060151 DOI: 10.1093/sleep/zsy141] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
31 Pittaras E, Colas D, Chuluun B, Allocca G, Heller C. Enhancing sleep after training improves memory in Down syndrome model mice. Sleep 2021:zsab247. [PMID: 34618890 DOI: 10.1093/sleep/zsab247] [Reference Citation Analysis]
32 Yun S, Wennerholm M, Shelton JE, Bonaventure P, Letavic MA, Shireman BT, Lovenberg TW, Dugovic C. Selective Inhibition of Orexin-2 Receptors Prevents Stress-Induced ACTH Release in Mice. Front Behav Neurosci 2017;11:83. [PMID: 28533747 DOI: 10.3389/fnbeh.2017.00083] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
33 Vakalopoulos C. The EEG as an index of neuromodulator balance in memory and mental illness. Front Neurosci 2014;8:63. [PMID: 24782698 DOI: 10.3389/fnins.2014.00063] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
34 Mieda M. The roles of orexins in sleep/wake regulation. Neuroscience Research 2017;118:56-65. [DOI: 10.1016/j.neures.2017.03.015] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 8.4] [Reference Citation Analysis]
35 Amodeo LR, Wills DN, Sanchez-Alavez M, Ehlers CL. Effects of an Orexin-2 Receptor Antagonist on Sleep and Event-Related Oscillations in Female Rats Exposed to Chronic Intermittent Ethanol During Adolescence. Alcohol Clin Exp Res 2020;44:1378-88. [PMID: 32424852 DOI: 10.1111/acer.14361] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Gamble MC, Katsuki F, Mccoy JG, Strecker RE, Mckenna JT. The dual orexinergic receptor antagonist DORA-22 improves the sleep disruption and memory impairment produced by a rodent insomnia model. Sleep 2019. [DOI: 10.1093/sleep/zsz241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
37 Roecker AJ, Cox CD, Coleman PJ. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. J Med Chem 2016;59:504-30. [PMID: 26317591 DOI: 10.1021/acs.jmedchem.5b00832] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
38 Steiner MA, Winrow CJ. Opportunities and perspectives for developing orexin receptor antagonists. Front Neurosci 2014;8:158. [PMID: 24971050 DOI: 10.3389/fnins.2014.00158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
39 Williams JT, Gatfield J, Roch C, Treiber A, Jenck F, Bolli MH, Brotschi C, Sifferlen T, Heidmann B, Boss C. Discovery and optimisation of 1-acyl-2-benzylpyrrolidines as potent dual orexin receptor antagonists. Med Chem Commun 2015;6:1054-64. [DOI: 10.1039/c5md00074b] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
40 De Boer P, Drevets WC, Rofael H, van der Ark P, Kent JM, Kezic I, Parapatics S, Dorffner G, van Gerven J, Beneš H, Keicher C, Jahn H, Seiden DJ, Luthringer R. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. J Psychopharmacol 2018;32:668-77. [PMID: 29848147 DOI: 10.1177/0269881118773745] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
41 Rappas M, Ali AAE, Bennett KA, Brown JD, Bucknell SJ, Congreve M, Cooke RM, Cseke G, de Graaf C, Doré AS, Errey JC, Jazayeri A, Marshall FH, Mason JS, Mould R, Patel JC, Tehan BG, Weir M, Christopher JA. Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis. J Med Chem 2020;63:1528-43. [PMID: 31860301 DOI: 10.1021/acs.jmedchem.9b01787] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
42 Gotter AL, Forman MS, Harrell CM, Stevens J, Svetnik V, Yee KL, Li X, Roecker AJ, Fox SV, Tannenbaum PL, Garson SL, Lepeleire ID, Calder N, Rosen L, Struyk A, Coleman PJ, Herring WJ, Renger JJ, Winrow CJ. Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man. Sci Rep 2016;6:27147. [PMID: 27256922 DOI: 10.1038/srep27147] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
43 Maehara S, Yuge N, Higashi C, Ota T, Furukawa J, Takeuchi T. Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM-878. Neuropsychopharmacol Rep 2020;40:182-9. [PMID: 32337858 DOI: 10.1002/npr2.12105] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Perrey DA, Zhang Y. Therapeutics development for addiction: Orexin-1 receptor antagonists. Brain Res 2020;1731:145922. [PMID: 30148984 DOI: 10.1016/j.brainres.2018.08.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
45 Johnson PL, Federici LM, Fitz SD, Renger JJ, Shireman B, Winrow CJ, Bonaventure P, Shekhar A. OREXIN 1 AND 2 RECEPTOR INVOLVEMENT IN CO2 -INDUCED PANIC-ASSOCIATED BEHAVIOR AND AUTONOMIC RESPONSES. Depress Anxiety 2015;32:671-83. [PMID: 26332431 DOI: 10.1002/da.22403] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
46 Dong Y, Li M, Wang S, Dong Y, Zhao H, Dai Z. Xingshentongqiao decoction mediates proliferation, apoptosis, orexin-A receptor and orexin-B receptor messenger ribonucleic acid expression and represses mitogen-activated protein kinase signaling. Chin Med J (Engl) 2015;128:98-104. [PMID: 25563321 DOI: 10.4103/0366-6999.147826] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
47 Bonaventure P, Yun S, Johnson PL, Shekhar A, Fitz SD, Shireman BT, Lebold TP, Nepomuceno D, Lord B, Wennerholm M, Shelton J, Carruthers N, Lovenberg T, Dugovic C. A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects. J Pharmacol Exp Ther 2015;352:590-601. [PMID: 25583879 DOI: 10.1124/jpet.114.220392] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 8.6] [Reference Citation Analysis]
48 Bonaventure P, Shelton J, Yun S, Nepomuceno D, Sutton S, Aluisio L, Fraser I, Lord B, Shoblock J, Welty N, Chaplan SR, Aguilar Z, Halter R, Ndifor A, Koudriakova T, Rizzolio M, Letavic M, Carruthers NI, Lovenberg T, Dugovic C. Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia. J Pharmacol Exp Ther 2015;354:471-82. [PMID: 26177655 DOI: 10.1124/jpet.115.225466] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
49 Treiber A, de Kanter R, Roch C, Gatfield J, Boss C, von Raumer M, Schindelholz B, Muehlan C, van Gerven J, Jenck F. The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468. J Pharmacol Exp Ther 2017;362:489-503. [DOI: 10.1124/jpet.117.241596] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]